Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.21 USD
+0.09 (4.25%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $2.22 +0.01 (0.45%) 6:34 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.21 USD
+0.09 (4.25%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $2.22 +0.01 (0.45%) 6:34 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Zacks News
Should You Buy Esperion Therapeutics (ESPR) Ahead of Earnings?
by Zacks Equity Research
Esperion Therapeutics (ESPR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
What's in Store for Intrexon (XON) in this Earnings Season?
by Zacks Equity Research
Intrexon Corporation (XON) will focus on the development of its pipeline candidates- FCX-013, FCX-007 in Q2.
What to Expect from Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme, Inc. (EPZM) plans to focus on the development of its lead candidate tazemetostat in Q2.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.
What's in the Cards for Endo (ENDP) this Earnings Season?
by Zacks Equity Research
Endo International plc (ENDP) remains focused on providing updates on its restructuring efforts across the Generics product as well as its manufacturing facility network in Q2.
Juno Therapeutics (JUNO) Q2 Earnings: Surprise in Store?
by Zacks Equity Research
Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q2.
The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva
Esperion Therapeutics (ESPR) Looks Good: Stock Gains 10.4%
by Zacks Equity Research
Esperion Therapeutics, Inc. (ESPR) shares jumped a little above 10% in the last trading session.
Here's Why Shares of Esperion Therapeutics (ESPR) Popped Today
by Megan Sanks
In a week full of good news for Esperion Therapeutics (ESPR), shares of the company closed the day up 10% to $48.28 per share.
Esperion's Combo Cholesterol Candidate Enters Phase III
by Zacks Equity Research
Esperion Therapeutics, Inc. (ESPR) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Zetia (10 mg) for an LDL-C lowering indication.
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6%
by Zacks Equity Research
Esperion Therapeutics, Inc. (ESPR) moved big last session, as its shares rose above 8% on the day.